Mesenchymal Stem Cell (MSC) Therapy for Tissue Regeneration — Regenerative Therapies
Multipotent stromal cells harvested from bone marrow, adipose, or umbilical cord tissue for immunomodulation and tissue repair.
Overview
Mesenchymal Stem Cells (MSCs) are multipotent stromal cells capable of differentiating into osteoblasts, chondrocytes, adipocytes, and other cell lineages. Originally isolated from bone marrow by Friedenstein in the 1960s, MSCs are now sourced from bone marrow (BM-MSCs), adipose tissue (AD-MSCs), umbilical cord/Wharton's jelly (UC-MSCs), and dental pulp. Their therapeutic potential extends beyond direct differentiation — MSCs exert potent paracrine effects through secretion of growth factors (VEGF, HGF, IGF-1), cytokines (IL-10, TGF-beta), and extracellular vesicles. They possess immunomodulatory properties, suppressing T-cell proliferation, modulating macrophage polarization (M1 to M2), and promoting regulatory T-cell expansion. Over 1,000 clinical trials are registered globally for conditions including osteoarthritis, GVHD, liver cirrhosis, COPD, and spinal cord injury. Despite extensive research, no MSC product has received full FDA approval for any indication in the United States, though several are approved internationally (e.g., Temcell/Prochymal for GVHD in Japan/Canada, Stemirac for spinal cord injury in Japan).
Indications
- Osteoarthritis and cartilage degeneration
- Graft-versus-host disease (GVHD)
- Liver cirrhosis and hepatic fibrosis
- Chronic obstructive pulmonary disease (COPD)
- Spinal cord injury
- Myocardial infarction and heart failure
- Diabetic wound healing
- Crohn's disease fistulae (Darvadstrocel/Alofisel - EMA approved)
- Autoimmune conditions (lupus, MS, rheumatoid arthritis)
Mechanism of Action
MSCs isolated from bone marrow aspirate, adipose lipoaspirate, or umbilical cord tissue. Expanded ex vivo through plastic-adherent culture to passage 3-5 (10-100 million cells per harvest)
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| MSCs (BM/AD/UC) | 1-2 million cells/kg | Single or series of 3-6 infusions | Standard IV infusion dose for systemic conditions (GVHD, autoimmune) |
| MSCs (BM/AD) | 20-100 million cells | Single injection, may repeat at 6-12 months | Direct intra-articular injection for knee osteoarthritis |
| MSCs (BM/UC) | 100-400 million cells | Single or series per protocol | Intrathecal delivery for spinal cord injury or neurological conditions |
Evidence Grade
GRADE C
Safety & Contraindications
- Not FDA-approved - investigational in the US
- Risk of infusion-related reactions (fever, chills, transient hypoxia)
- Theoretical risk of ectopic tissue formation or tumorigenicity (not observed in clinical trials to date)
- Pulmonary first-pass effect: IV-administered MSCs initially trap in lung capillaries
- Source-dependent variability: BM-MSCs, AD-MSCs, UC-MSCs differ in potency and immunogenicity
- Donor variability and passage number affect therapeutic efficacy
- Unregulated stem cell clinics pose significant safety risks (FDA warning letters issued)
- Cryopreservation may reduce viability and potency vs fresh cells
- Long-term safety data beyond 5-10 years limited
- FDA has issued multiple warning letters to unregulated stem cell clinics